ArticleJournal of medical virology2025
TIMP-2 as a Potential Indicator of Persistent Arthralgia in Chikungunya: Evidence From a Brazilian Cohort Study.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chikungunya virus (CHIKV) infection can trigger a sustained inflammatory response, often leading to chronic musculoskeletal pain. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may contribute to the persistence of arthralgia through their involvement in joint tissue remodeling and degradation. This study aimed to evaluate the potential of MMPs and TIMPs as plasma biomarkers of persistent arthralgia in individuals diagnosed with Chikungunya Fever (CHIKF). A prospective cohort study was conducted using plasma samples from 133 CHIKF-positive individuals recruited during the acute or post-acute phases. Sociodemographic and clinical data were collected at outpatient visits. At 90 days post-symptom onset, participants were assessed for persistent arthralgia using a self-reported Visual Analog Scale (VAS) for joint pain and categorized into two groups: Recovered (VAS 0-3, n = 71) or Persistent Arthralgia (VAS 4-10, n = 62). Plasma levels of MMP-2, MMP-9, and TIMP-2 were quantified using multiplex bead-based ELISA (LegendPlex), while MMP-1, MMP-3, MMP-14/MT1-MMP, and TIMP-1 were measured via sandwich ELISA. Plasma samples from 51 CHIKV-negative individuals were used as controls. Statistical analyzes were performed using GraphPad Prism v9.0, IBM SPSS Statistics and Stata. Among post-acute participants, lower MMP-2 levels were significantly associated with recovery compared to those with persistent arthralgia and to controls. TIMP-2 levels varied significantly across clinical outcomes, supporting its involvement in CHIKV-induced pathology. Multivariate analysis identified swollen joints, skin rash, and elevated TIMP-2 levels during the post-acute phase as independent predictors of persistent arthralgia in the chronic phase. No significant differences were observed for MMP-1, MMP-3, MMP-9, MMP-14, or TIMP-1. These findings suggest a potential role for TIMP-2 and musculoskeletal manifestations as early indicators of chronic joint symptoms following CHIKV infection. Further studies are needed to validate these biomarkers and better understand the mechanisms underlying chronic Chikungunya-related arthralgia across diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.